The buying volume does tend to spike ahead of pending news.
Given that their strength and upside potential are rooted in a combination of intellectual property and management personnel, it does seem that they would benefit from more frequent news releases.
They do not need to be major announcements, however some type of updates on lab pursuits, on clinical time tables, and/or facts pertaining to their upper echelon of management would certainly help keep BMSN on the radar screen of outsiders.
The stock sits stagnant for days on end, even weeks, due to a deafening silence from the PR group whose job is to promote the business and generate interest in the business.
Frankly, I think a new PR firm would be a nice move by BMSN: or a modified news announcement policy at the very least.
Market Data 
Markets 
AI
